| State |
Study Site |
Indication |
Title |
Description |
Details |
| TX |
Texas Oncology - Baylor Charles Sammons Cancer Center |
Metastatic Melanoma |
An Open-Label, Multi-Center Phase II Study of Continuous Oral Dosing of R05185426 in Patients with Metastatic Melanoma, #NP22657 |
View |
| TX |
Texas Oncology - Baylor Charles Sammons Cancer Center |
Renal Cell Carcinoma |
Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma. |
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Bladder Cancer |
Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma |
|
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Bedford (Edwards Cancer Center )
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Brain Cancer |
A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial Of Memantine For Prevention Of Cognitive Dysfunction In Patients Receiving Whole-Brain Radiotherapy (RTOG 0614) |
|
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-BedfordEdwards Cancer Center )
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Brain Cancer |
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma (RTO |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East
|
Breast Cancer |
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford
|
Breast Cancer |
A Multi-Center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-Amplified Metastatic HER2 Negative Breast Cancer |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Grapevine,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Tyler
|
Breast Cancer |
A Phase 2, multicenter, randomized, open-label study comparing eribulin mesylate and ixabepilone in causing or exacerbating neuropathy in patients with advanced breast cancer |
|
View |
TX
|
Texas Oncology-Longview,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Midland Allison Cancer Center,
Texas oncology-Weslaco
|
Breast Cancer |
A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment with a Non-Steroidal Aromatase I |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Breast Cancer |
A Phase 3, Randomized, Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2–Positive Locally Advanced or Metastatic Breast Cancer |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Lewisville,
Texas Oncology-Longview,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Breast Cancer |
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer |
|
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-BedfordEdwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Breast Cancer |
A Phase III Clinical Trial Comparing Trastuzumab Given Concurently with Radiation and Radiation Alone for Women with Her2-Postive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Breast Cancer |
A Randomized Double Blind Placebo-Controlled Trial of Neratinib (HKI-272) Following Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer
|
|
View |
TX
|
Texas Oncology-Bedford (Edwards Cancer Center )
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Breast Cancer |
A Randomized Phase III Study of Conventional Whole Breast
Irradiation (WBI) Versus Partial Breast Irradiation (PBI)
for Women with Stage 0, I, or II Breast Cancer (RTOG 0413) |
|
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Plano East,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Breast Cancer |
A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/neu Over-expressing Locally Advanced or Metastatic Breast Cancer
|
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Cedar Park,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Breast Cancer |
A randomized phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel, as first line therapy in women with HER2-positive locally advanced or metastatic breast cancer |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Sherman,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Breast Cancer |
A Randomized, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer |
|
View |
TX
|
Texas Oncology-Bedford,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Southwest Fort Worth
|
Breast Cancer |
A Randomized, Phase III, Open-label Study of Lapatinib plus
Trastuzumab versus Trastuzumab as Continued HER2
Suppression Therapy after Completion of First- or Second-line
Trastuzumab plus Chemotherapy in Subjects with HER2-
positive Metastatic Breast |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Breast Cancer |
Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women who have Hormone Receptor-positive Advanced Breast Cancer Previously Treated with an Aromatase Inhibitor |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Tyler
|
Breast Cancer |
Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers.
|
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Medical City Dallas,
Texas Oncology-Memorial City,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Breast Cancer |
Randomized Phase II Trial of Letrozole with or without Dasatinib as First and Second-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic |
|
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Colon Cancer |
A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-line Treatment in Subjects with Metastatic Colorectal Cancer with Wild-Type KRAS tumors |
|
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Colon Cancer |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-Line Treatment of KRAS-Mutant Colorectal Carcinoma |
|
View |
TX
|
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Tyler
|
Colon Cancer |
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of
Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colo |
|
View |
TX
|
Texas Oncology-Bedford (Edwards Cancer Center )
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Esophageal Cancer |
A Phase III Trial Evaluating The Addition Of Cetuximab To Paclitaxel, Cisplatin, And Radiation For Patients With Esophageal Cancer Who Are Treated Without Surgery (RTOG 0436)
|
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Longview,
Texas Oncology-Plano East,
Texas Oncology-South Austin,
Texas Oncology-Waco
|
Fallopian Tube Cancer |
A Randomized Phase II Trial Comparing Ec145 And Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus Pld Alone In Subjects With Platinum-Resistant Ovarian Cancer (PRECEDENT Trial) |
|
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Lewisville,
Texas Oncology-Longview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Gastric Cancer |
Phase II trial of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma |
|
View |
TX
|
Texas Oncology-Tyler
|
GI Stromal Tumor (GIST) |
A randomized, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Kidney Cancer |
Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma |
|
View |
TX
|
Texas Oncology-Medical City Dallas,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Tyler
|
Leukemia |
A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
EXTENSION ONLY |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Medical City Dallas,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Leukemia |
A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia |
|
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-BedfordEdwards Cancer Center )
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Longview,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Waco,
Texas oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Liver Cancer |
Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with SorafeNib (GIDEON) |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Lewisville,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Tyler
|
Lung Cancer |
A Multi-center Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have E |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Denton South,
Texas Oncology-Longview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Lung Cancer |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC) |
|
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Bedford (Edwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Lung Cancer |
A RANDOMIZED PHASE III COMPARISON OF STANDARD- DOSE (60 Gy) VERSUS HIGHDOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB (IND# 103444)IN PATIENTS WITH STAGE IIIA/IIIB NON-SMALL CELL LUNG CANCER (RTO |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Longview,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lung Cancer |
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemot |
|
View |
TX
|
Texas Oncology-Sugar Land
|
Lung Cancer |
A randomized, phase III, open-label study of oral topotecan plus
whole-brain radiation therapy (WBRT) compared with WBRT
alone in patients with brain metastases from Non-Small Cell
Lung Cancer |
|
View |
TX
|
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Medical City Dallas,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Lung Cancer |
FORTIS-M: A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Lewisville,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas oncology-Weslaco
|
Lung Cancer |
Phase II trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70 |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Grapevine,
Texas Oncology-Lewisville,
Texas Oncology-Longview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Lung Cancer |
Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or I |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lymphomas |
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma |
|
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler
|
Lymphomas |
C18083/3064/NL/MN: An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, an |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Plano East,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Lymphomas |
PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin |
|
View |
TX
|
Texas Oncology-Bedford
|
Melanoma |
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma. 111482 |
|
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth
|
Melanoma |
A Randomized Phase III Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma |
|
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Paris
|
Myelomas |
A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Longview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Myelomas |
Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE® (Bortezomib), Thalidomide, and Dex |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Longview,
Texas Oncology-Plano East,
Texas Oncology-South Austin,
Texas Oncology-Waco
|
Ovarian Cancer |
A Randomized Phase II Trial Comparing Ec145 And Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus Pld Alone In Subjects With Platinum-Resistant Ovarian Cancer (PRECEDENT Trial) |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-South Austin,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Ovarian Cancer |
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab
(MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-South Austin
|
Ovarian Cancer |
Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in
patients with advanced ovarian cancer |
|
View |
TX
|
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Tyler
|
Pancreatic Cancer |
A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen Versus a |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Longview,
Texas Oncology-Plano East,
Texas Oncology-South Austin,
Texas Oncology-Waco
|
Peritoneal Cancer |
A Randomized Phase II Trial Comparing Ec145 And Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus Pld Alone In Subjects With Platinum-Resistant Ovarian Cancer (PRECEDENT Trial) |
|
View |
TX
|
Texas Oncology-Arlington South,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Deke Slayton Cancer Center
|
Prostate Cancer |
A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Hormone-Refractory Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen |
|
View |
TX
|
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Prostate Cancer |
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer (CRPC) |
|
View |
TX
|
Texas Oncology-BedfordEdwards Cancer Center )
Texas Oncology-Denton South,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Prostate Cancer |
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer RTOG 0815 |
|
View |
TX
|
Texas Oncology-Bedford (Edwards Cancer Center )
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Fort Worth 8th Ave.,
Texas Oncology-Klabzuba,
Texas Oncology-Longview,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Sherman,
Texas Oncology-Sugar Land
|
Prostate Cancer |
A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (Spport) In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy (RTOG 0534) |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford
|
Renal Cancer |
A Treatment Protocol for Patients continuing from a prior SU011248 Protocol
|
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Bedford,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Tyler,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Renal Cancer |
Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center
|
Solid Tumors |
A Phase 1, Multicenter, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor-alpha (PDGFR-alpha), |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Solid Tumors |
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Solid Tumors |
A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT), Safety and Pharmacokinetics of PG-11047 when Used in Individual Combinations with 1) Gemcitabine or 2) Docetaxel or 3) Be |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Cedar Park,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-South Austin,
Texas Oncology-Tyler
|
Solid Tumors |
A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors |
|
View |
TX
|
Texas Oncology-Austin Central,
Texas Oncology-Baylor Charles A. Sammons Cancer Center,
Texas Oncology-Tyler
|
Solid Tumors |
An open label Phase II trial of BIBW 2992 in genetically pre-screened cancers with EGFR and/or HER2 gene amplifications or EGFR activating mutations |
|
View |
TX
|
Texas Oncology-Baylor Charles A. Sammons Cancer Center
|
Solid Tumors |
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors ( Pancreas, Melanoma,Colon (BRAF),NSCLC(KRAS), other |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Dallas Presbyterian Hospital,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Garland,
Texas Oncology-Grapevine,
Texas Oncology-Longview,
Texas Oncology-McAllen South Second Street,
Texas Oncology-Medical City Dallas,
Texas Oncology-Mesquite,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Paris,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco,
Texas oncology-Weslaco,
Texas Oncology-Wichita Falls Texoma Cancer Center
|
Supportive Care |
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemot |
|
View |
TX
|
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Odessa West Texas Cancer Center,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Thromboses/Coagulation |
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects with Symtomatic Deep-Vein Thrombosis and/or |
|
View |
TX
|
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Grapevine,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Urothelial Cancer |
An open label, single-arm, Phase II trial of intravenous BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer of the bladder, renal pelvis, or ureters after failure of prior chemotherapy |
|
View |
TX
|
Texas Oncology-Abilene,
Texas Oncology-Amarillo,
Texas Oncology-Arlington South,
Texas Oncology-Austin Central,
Texas Oncology-Austin Midtown,
Texas Oncology-Austin North,
Texas Oncology-Beaumont (Mamie McFaddin Ward Cancer Center )
Texas Oncology-Bedford,
Texas Oncology-Cedar Park,
Texas Oncology-Deke Slayton Cancer Center,
Texas Oncology-Denton South,
Texas Oncology-El Paso Cancer Treatment Center Gateway,
Texas Oncology-El Paso Cancer Treatment Center Grandview,
Texas Oncology-Fort Worth 12th Ave.,
Texas Oncology-Longview,
Texas Oncology-Medical City Dallas,
Texas Oncology-Methodist Charlton Cancer Center,
Texas Oncology-Midland Allison Cancer Center,
Texas Oncology-Plano East,
Texas Oncology-Plano West,
Texas Oncology-Round Rock,
Texas Oncology-San Marcos,
Texas Oncology-Seton Williamson,
Texas Oncology-Sherman,
Texas Oncology-South Austin,
Texas Oncology-Southwest Fort Worth,
Texas Oncology-Sugar Land,
Texas Oncology-Tyler,
Texas Oncology-Waco
|
Urothelial Cancer |
Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma |
|
View |